What does the future of immunotherapy look like, and how is CRI evolving to make the greatest impact? CRI’s CEO and Director of Scientific Affairs, Dr. Jill O’Donnell-Tormey, CRI Scientific Advisory Council director Dr. James P. Allison, and Scientific Advisory Council associate director Dr. E. John Wherry describe how CRI funded scientists are driving the future of cancer immunotherapy research, and how CRI is harnessing data to unlock next-generation cures for more cancers.